Protein therapeutics: a summary and pharmacological classification

By B. Leader, Quentin J. Baca, D. Golan. Nature reviews. Drug discovery, 2008

1,959 citations recorded by the source corpus.

Subfields: Biotechnology, Molecular Biology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/4c1a93f3e02b13e2d7bcbbaaa9110ab4e91176c0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biotechnology

In Molecular Biology

In Radiology, Nuclear Medicine and Imaging

Citations in the corpus

Protein structure generation via folding diffusion (2022, background): “Due to their ability to perform complex functions with high specificity, proteins have been extensively studied as a therapeutic medium (Leader et al., 2008; Kamionka, 2011; Dimitrov, 2012) and constitute a rapidly growing segment of approved therapies (H Tobin et al.”
The safety and side effects of monoclonal antibodies (2010, background): “Among the advantages of protein therapeutics such as mAbs over conventional low-molecular-mass drugs are their high specificities, which facilitates precise action, and their long half-lives, which allows infrequent dosin”
The CamSol method of rational design of protein mutants with enhanced solubility. (2015, background): “Proteins are attractive diagnostic and therapeutic molecules because of their functional versatility and specificity, as well as their inherently low toxicity [1–4].”
Molecular tracing of confiscated pangolin scales for conservation and illegal trade monitoring in Southeast Asia (2015, background): “However, pangolin scales consist of keratin, which has no proven pharmacological effects (Leader et al., 2008).”
How were new medicines discovered? (2011, background): “The biologics were further categorized according to their pharmacological action as described by Leader, Baca and Gola”
Fusion Protein Linkers: Property, Design and Functionality (2012, background): “-PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript fusion proteins drugs including Enbrel® (tumor necrosis factor/Fc-IgG1), Ontak® (Interleukin-2/diphtheria toxin), Orencia® (Cytotoxic T-Lymphocyte Antigen-4/Fc-IgG1), Amevive® (Leukocyte function antigen-3/Fc-IgG1), Arcal”
New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics (2013, background): “By 2000, only about 500 drug targets had been reported [136, 137], among which only 120 drug targets are actually marketed [138].”
Rethinking Protein Drug Design with Highly Accurate Structure Prediction of Anti-CRISPR Proteins (2021, background): “Compared to small-molecule drugs, the major advantage of protein therapeutics is improved target specificity and reduced immunogenicity due to their proteinaceous nature [5].”